Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Clynes RA, Towers TL, Presta LG, Ravetch JV.

Nat Med. 2000 Apr;6(4):443-6.

PMID:
10742152
2.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.

Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Review.

PMID:
10482195
3.

Fc receptors and their interaction with complement in autoimmunity.

Schmidt RE, Gessner JE.

Immunol Lett. 2005 Aug 15;100(1):56-67. Review.

PMID:
16125792
4.

FcgammaR: The key to optimize therapeutic antibodies?

Sibéril S, Dutertre CA, Fridman WH, Teillaud JL.

Crit Rev Oncol Hematol. 2007 Apr;62(1):26-33. Epub 2007 Jan 19. Review.

PMID:
17240158
5.

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Review.

PMID:
23543215
6.

Inhibitory Fc gamma receptors: from gene to disease.

Stefanescu RN, Olferiev M, Liu Y, Pricop L.

J Clin Immunol. 2004 Jul;24(4):315-26. Review.

PMID:
15163888
7.

Fc gamma receptors and cancer.

Cassard L, Cohen-Solal J, Camilleri-Broët S, Fournier E, Fridman WH, Sautès-Fridman C.

Springer Semin Immunopathol. 2006 Dec;28(4):321-8. Epub 2006 Nov 10. Review.

PMID:
17096153
9.

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.

DiLillo DJ, Ravetch JV.

Cancer Immunol Res. 2015 Jul;3(7):704-13. doi: 10.1158/2326-6066.CIR-15-0120. Review.

10.

[Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies].

Lejeune J, Thibault G, Cartron G, Ohresser M, Watier H.

Bull Cancer. 2010 May;97(5):511-22. doi: 10.1684/bdc.2010.1077. Review. French.

11.

Engineered antibody for treating lymphoma.

Stevenson GT, Anderson VA, Leong WS.

Recent Results Cancer Res. 2002;159:104-12. Review.

PMID:
11785834
12.

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A.

J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1. Review.

13.

Three major uncertainties in the antibody therapy of cancer.

Stevenson GT.

Haematologica. 2014 Oct;99(10):1538-46. doi: 10.3324/haematol.2013.084640. Review.

14.

Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?

Eccles SA.

Breast Cancer Res. 2001;3(2):86-90. Epub 2000 Dec 20. Review.

15.

Understanding and circumventing resistance to anticancer monoclonal antibodies.

Reslan L, Dalle S, Dumontet C.

MAbs. 2009 May-Jun;1(3):222-9. Epub 2009 May 24. Review.

16.

Platelet activation via binding of monoclonal antibodies to the Fc gamma receptor II.

Wilkinson JM, Hornby EJ, Authi KS.

Adv Exp Med Biol. 1993;344:221-8. Review. No abstract available.

PMID:
8209790
17.

FcγRIIB as a key determinant of agonistic antibody efficacy.

White AL, Beers SA, Cragg MS.

Curr Top Microbiol Immunol. 2014;382:355-72. doi: 10.1007/978-3-319-07911-0_16. Review.

PMID:
25116108
18.

FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.

Nimmerjahn F, Gordan S, Lux A.

Trends Immunol. 2015 Jun;36(6):325-36. doi: 10.1016/j.it.2015.04.005. Epub 2015 May 13. Review.

PMID:
25981969
19.

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies.

Kim JM, Ashkenazi A.

J Exp Med. 2013 Aug 26;210(9):1647-51. doi: 10.1084/jem.20131625. Review.

20.

Of mice and men: the need for humanized mouse models to study human IgG activity in vivo.

Lux A, Nimmerjahn F.

J Clin Immunol. 2013 Jan;33 Suppl 1:S4-8. doi: 10.1007/s10875-012-9782-0. Epub 2012 Sep 5. Review.

PMID:
22948744

Supplemental Content

Support Center